Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I open-label single-center study of RM-1929 photoimmunotherapy in recurrent head and neck squamous cell carcinoma
jRCT2031200133Phase 1Completed
- Sponsor
- Rakuten Medical, Inc.
- Start
- Mar 2018
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cetuximab sarotalocan sodium in head and neck squamous cell carcinoma (HNSCC), sponsored by Rakuten Medical, Inc. Primary endpoint: Safety. Started Mar 2018; status: completed.
02
Drugs
cetuximab sarotalocan sodium
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCT2031200133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200133.